LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open. 2020 05; 5(3):e000748.

View in: PubMed

subject areas

Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Female
Humans
Lung Neoplasms
Male
Mutation
Prospective Studies
Taxoids

authors with profiles

Marina Chiara Garassino